Overview of Zerodol SP

Zerodol SP is a prescription-only, oral fixed-dose combination (FDC) drug product presented as a tablet, defined by its triple pharmacological action. It combines an NSAID, an analgesic/antipyretic, and a Systemic Enzyme Preparation. This combination is engineered to target the three core components of injury or inflammatory conditions: pain, inflammation, and associated swelling.

Quick Facts

Property	Description
Active Ingredients	Aceclofenac, Paracetamol, Serratiopeptidase
Form	Oral Tablet (Fixed-Dose Combination)
Pharmacological Class	NSAID, Analgesic, Systemic Enzyme
Common Use Principle	Multimodal relief of pain, inflammation, and swelling
Origin	Synthetic (Aceclofenac, Paracetamol) and Microorganism-derived (Serratiopeptidase)

What Type of Medicine is Zerodol SP?

Zerodol SP is an allopathic medicine formulated as an oral tablet that belongs to the pharmacological class of Non-steroidal Anti-inflammatory Drugs (NSAIDs), combined with two other therapeutic agents. It is defined as an FDC because it contains three different active pharmaceutical ingredients within the same tablet, distinguishing it from single-ingredient NSAID products.

The three-part composition is clinically recognized for its efficacy in managing inflammatory and painful musculoskeletal conditions. The Aceclofenac component is noted for its potent anti-inflammatory and analgesic properties, which is achieved through inhibiting the synthesis of prostaglandins. This means the drug helps ease discomfort by reducing the body’s ability to create the chemical signals that cause pain and swelling.

Composition and General Purpose

The tablet contains three principal active ingredients [INN]: Aceclofenac, Paracetamol (also known as Acetaminophen), and Serratiopeptidase. Each ingredient has a specific role: Aceclofenac reduces inflammation; Paracetamol contributes to the medication's analgesic (pain-relieving) and antipyretic (fever-reducing) effects by acting centrally in the nervous system.

The general purpose is to provide multimodal action for managing symptoms where pain, inflammation, and edema (swelling) coexist. Within this combination, the enzyme Serratiopeptidase has a role in reducing swelling and breaking down abnormal protein deposits, aiding in the resolution of local edema. The targeted therapeutic approach aims for efficient symptomatic relief across a range of conditions involving tissue injury or inflammation, such as managing acute pain following dental procedures or soft tissue injuries.

What side effects are possible with Zerodol SP?

Possible Side Effects and Safety Information

The safety profile of Zerodol SP, a fixed-dose combination containing an NSAID (Aceclofenac) and Paracetamol, is defined by regulatory documents based on the established risks of its primary components. Adverse reactions are formally classified by frequency and grouped according to the body systems affected, which is the standard structure used by government regulatory agencies.

Frequency-Classified Adverse Reactions

The official labeling classifies many effects as Common (occurring in 1/100 to <1/10 individuals), including dizziness, dyspepsia, abdominal pain, and elevated liver enzymes (transaminases). Uncommon reactions may involve vomiting, flatulence, rash, and pruritus. Rare and Very Rare classifications are applied to severe events.

System-Organ-Classes and Serious Risks

Adverse effects are documented across various System-Organ Classes, including Gastrointestinal, Hepatobiliary, Nervous System, and Skin/Subcutaneous Tissue Disorders. Regulatory documents emphasize the risk of Serious Adverse Reactions, particularly concerning the NSAID component.

Gastrointestinal Ulceration and Bleeding: These events, which may be fatal, are officially documented and can occur at any time during treatment, with or without warning symptoms.
Severe Hepatotoxicity: Due to the Paracetamol component, risk of severe liver toxicity and hepatic failure is a primary safety concern, particularly with chronic use or misuse.
Cardiovascular Events: The risk of serious arterial thrombotic events, such as myocardial infarction and stroke, is documented as a class-effect warning for NSAIDs, increasing with the duration and dose of exposure.

Population-Specific Safety Constraints

Specific safety considerations are defined for certain populations. Older adults are noted to be at an increased risk of serious gastrointestinal adverse reactions. The drug is contraindicated in individuals with severe pre-existing conditions, including severe heart failure, active gastrointestinal haemorrhage, or severe hepatic or renal impairment. Regulatory warnings also note that the NSAID component may impair female fertility and is generally not recommended in the last trimester of pregnancy.

Overdose and Emergency Response

Overdose with this fixed-dose combination product may initially present with nonspecific symptoms such as pallor, nausea, vomiting, and abdominal pain. Symptoms may be delayed for up to 48 hours. However, due to the Paracetamol component, the most severe outcome is delayed severe liver injury that can rapidly progress to hepatic failure, requiring critical intervention. The Aceclofenac component increases the potential for adverse events like acute renal failure and serious gastrointestinal bleeding.

Official Emergency Requirements

Official regulatory sources mandate that the patient seek immediate medical attention and undergo urgent hospital referral for any suspected overdose, regardless of the severity of initial symptoms. This action is necessary because of the potential for silent or delayed toxicity.

Severe manifestations documented include cerebral oedema, cardiac arrhythmias, and convulsions. Management proceeds under established guidelines, which include the consideration of activated charcoal if ingestion was recent. N-acetylcysteine is the specific regulatory-documented treatment for mitigating Paracetamol-related hepatotoxicity. Comprehensive hospital monitoring is required to assess for delayed organ damage. Individuals with non-cirrhotic alcoholic liver disease or those who are glutathione deplete are noted to be at a higher risk for severe toxicity.

Therapeutic Uses of Zerodol SP

Quick Facts: Therapeutic Domains

Joint and Muscle Discomfort: Provides temporary relief for symptoms associated with various musculoskeletal conditions, including osteoarthritis and rheumatoid arthritis.
Inflammation and Swelling: May be used to manage localized swelling and inflammation following injury or surgery.
Pain and Stiffness: Helps to address discomfort and morning stiffness linked to conditions like ankylosing spondylitis.
Fever: Contributes to the reduction of fever associated with inflammatory processes.

Zerodol SP: Main Uses and Expected Benefits

Zerodol SP is a combination medication indicated for the short-term symptomatic relief of pain, inflammation, and associated discomfort. Its primary use is in the management of acute flare-ups and chronic conditions that involve joint and muscle pain.

It is typically utilized to help manage the signs and symptoms of inflammatory joint conditions such as rheumatoid arthritis and osteoarthritis. For individuals with ankylosing spondylitis, this medication may assist in alleviating the morning stiffness and pain that characterize the condition. Additionally, the formulation may be prescribed for general pain and inflammation management following musculoskeletal injuries or certain surgical procedures, contributing to a more comfortable recovery process.

The inclusion of an enzyme component is intended to support the resolution of localized swelling (oedema) and facilitate the body's natural processes associated with tissue maintenance. Overall, the treatment aims to provide relief from discomfort, promote reduction in swelling, and may assist in enhancing mobility and movement when used as directed by a healthcare professional.

Eligibility and Restrictions for Use

Official Eligibility and Restriction Profile

Zerodol SP (Aceclofenac, Paracetamol, Serratiopeptidase) is subject to strict eligibility rules based on the components' regulatory profiles, primarily the NSAID (Aceclofenac) and Paracetamol.

Eligibility Scope	Status / Rule
Populations for whom use is contraindicated	Individuals with known hypersensitivity to any component; patients with a history of active or recurrent peptic ulcer/GI haemorrhage; those with severe heart failure (NYHA Class II-IV); or severe hepatic/renal failure; and patients in the last trimester of pregnancy.
Age-related eligibility rules	Children and Adolescents (under 18 years): Use is not recommended as safety and efficacy are not established. Older Adults (Geriatrics): Use requires caution and monitoring due to increased susceptibility to adverse effects.
Pregnancy and lactation eligibility status	Pregnancy: Contraindicated in the last trimester. Not recommended during the first two trimesters unless medically necessary. Lactation/Breastfeeding: Not recommended; safety is not established.
Condition-specific eligibility rules	Use requires caution in patients with a history of GI issues, mild-to-moderate impairment of cardiac, renal, or hepatic function, and conditions where NSAIDs precipitate asthma.

These official statements define who can and cannot use the medicine by establishing absolute prohibitions based on severe organ failure or active bleeding risk, and classifications that necessitate close monitoring for other vulnerable groups.

What should I know about interactions with other medicines?

The official regulatory interaction profile for this medicine is primarily defined by the documented interactions of its Aceclofenac (NSAID) and Paracetamol components.

Documented Drug Interactions

Classification	Interacting Agents	Official Interaction Outcome
Hemorrhage Risk	Oral Anticoagulants (e.g., Warfarin), SSRIs	Significantly increased risk of bleeding and hemorrhage.
Therapeutic Attenuation	Diuretics, Antihypertensives	Reduction in the intended natriuretic (water/salt excretion) or blood pressure-lowering effect.
Exposure Modification	Lithium, Digoxin, Methotrexate	Increased plasma concentrations of the co-administered drug due to changes in renal clearance.

Product Restrictions and Substance Interactions

Official labeling mandates formal restrictions on co-administration with other Non-steroidal Anti-inflammatory Drugs (NSAIDs) and other Paracetamol-containing products due to cumulative toxicity risks. The use of the Paracetamol component in combination with alcohol is formally linked to an enhanced risk of severe liver damage (hepatotoxicity).

Separation of administration is required for Cholestyramine to prevent a reduction in the absorption of the Paracetamol component. Furthermore, specific cautions are noted for the elderly and those with renal impairment, as co-administration of the NSAID component with certain antihypertensive agents may lead to deterioration of renal function, as stated in prescribing information.

Mechanism of Action

Zerodol SP is defined by three distinct mechanistic actions that modulate key physiological processes related to nociception, the inflammatory cascade, and tissue fluid dynamics.

Dual Modulation of Nociceptive Signal Pathways

This combination engages two separate molecular approaches to modify nociceptive signaling: peripherally and centrally. The Aceclofenac component works by competitively inhibiting Cyclooxygenase ( COX) enzymes at the site of inflammation, thereby suppressing the synthesis of PGE2 that sensitizes sensory nerves. Concurrently, Paracetamol acts primarily in the Central Nervous System ( CNS) by modulating the CB1 receptor system, altering the descending inhibitory pain pathways and modulating the processing of nociceptive signals. This dual mechanism targets both the peripheral generation of nociceptive signals and central signal processing.

Clearance of Tissue Exudate via Proteolytic Action

The third active ingredient, Serratiopeptidase, acts through an enzymatic mechanism that influences the physical characteristics of inflammatory exudate. As a proteolytic enzyme, it performs direct hydrolytic cleavage of abnormal, non-viable proteins—such as fibrin and HMW kininogens—that accumulate in inflammatory fluid. This degradation reduces the viscosity of the fluid and facilitates enhanced lymphatic drainage, leading to the physiological effect of local swelling (edema) clearance.

Dosage and Administration Information

Zerodol SP is an oral fixed-dose combination (FDC) tablet, and its administration is defined by guidelines for its components. The established route of administration is oral, with no alternative injectable or topical forms available for this product. The standard dosing regimen for adults is one tablet taken twice daily (BID), which aligns with the established maximum 200 mg daily dose for the Aceclofenac component. The total daily intake must not exceed two tablets, which is the maximum labeled dose for the FDC.

To minimize the risk of gastrointestinal irritation linked to the NSAID component, the tablet is instructed to be taken with or immediately after food or milk. For the drug's intended release and proper absorption, the tablet must be swallowed whole and must never be crushed, broken, or chewed. This procedural requirement is critical for maintaining the intended release profile of the triple-drug formulation.

Guidance emphasizes that the medication is intended for short-term use only, and administration should be limited to the shortest duration necessary to control acute symptoms. Specific use patterns apply to certain populations: the medicine is not recommended for use in children and adolescents under the age of 18 due to lack of sufficient data. For older adults, the lowest effective dose should be used. Additionally, patients with mild hepatic impairment may require a reduced regimen, potentially limiting administration to one tablet daily based on the component's guidelines.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Zerodol SP is a fixed-dose combination containing aceclofenac (a non-steroidal anti-inflammatory drug), paracetamol (an analgesic/antipyretic), and serratiopeptidase (a proteolytic enzyme). Clinical research has primarily focused on evaluating the role of this combination in managing pain, swelling, and inflammation associated with musculoskeletal and postoperative conditions.

Clinical Findings in Pain and Inflammation

Studies have investigated the combination’s use in conditions such as osteoarthritis (OA) flare-ups and postoperative dental pain management.

Osteoarthritis: Comparative, open-label studies have been conducted to evaluate the combination therapy against monotherapy (aceclofenac alone) in patients experiencing acute painful OA flare-ups. Research findings suggest that the combination of aceclofenac and paracetamol may show a quicker onset of pain relief compared to aceclofenac monotherapy.
Postoperative Care: In the context of dental implant placement, retrospective studies have been conducted to understand prescribing patterns, indicating that the triple combination is commonly administered for managing pain and inflammation after surgery.

Tolerability and Safety Findings

Clinical data and surveillance reports indicate that the most commonly reported adverse events across the constituent ingredients include gastrointestinal complaints. For instance, aceclofenac has been compared with other NSAIDs (such as diclofenac) in OA studies, and some trials have reported a lower incidence of certain gastrointestinal side effects with aceclofenac. The overall rate of discontinuation due to adverse events is generally reported in clinical studies, but long-term use of NSAIDs may require monitoring of renal and hepatic function.

Frequently Asked Questions (FAQ)

Common questions about Zerodol SP (FAQ)

Q: How long does the pain relief from Zerodol SP typically last?

A: Official prescribing information supports a twice-daily (BID) dosing regimen. The twice-daily dosing regimen implies that the duration of action is expected to cover the period between scheduled doses.

Q: Why does Zerodol SP contain three different components (Aceclofenac, Paracetamol, Serratiopeptidase)?

A: The formulation is officially described as a Fixed-Dose Combination (FDC) designed for a multimodal approach to symptom relief. This means it combines Aceclofenac for anti-inflammatory action, Paracetamol for pain and fever reduction, and Serratiopeptidase to help address swelling and inflammatory fluid.

Q: What is the role of Serratiopeptidase in Zerodol SP?

A: Serratiopeptidase is a proteolytic enzyme that influences the inflammatory fluid that accumulates at the site of injury. According to official documents, its action helps to reduce local swelling, or edema, as part of the overall therapeutic effect.

Q: Is Zerodol SP the same as other medicines that only contain Aceclofenac?

A: No. Official documents specify that Zerodol SP is a Fixed-Dose Combination (FDC) that contains three active pharmaceutical ingredients: Aceclofenac, Paracetamol, and Serratiopeptidase. This triple combination makes it distinct from products that contain Aceclofenac as a single component.

Q: What is the difference between Zerodol SP and a simple paracetamol tablet?

A: Zerodol SP is defined in official product information as a three-component medicine. In addition to the Paracetamol component, it also includes Aceclofenac (an NSAID) and Serratiopeptidase (a systemic enzyme), which are not present in a simple Paracetamol tablet.

Q: Can Zerodol SP be used for pain in joints like arthritis?

A: Official indications cover joint-related conditions. Clinical evidence has investigated the combination for use in managing pain and inflammation associated with conditions such as osteoarthritis (OA) flare-ups and rheumatoid arthritis.

Q: Is Zerodol SP used to help reduce swelling after an injury?

A: Official indications describe the medicine as being used for the multimodal relief of symptoms where pain, inflammation, and swelling (edema) coexist. This includes use for the resolution of swelling and pain following soft tissue injury.

Q: Do I need a prescription to get Zerodol SP in most countries?

A: According to the official product status, Zerodol SP is formally classified as a prescription-only drug product.

Q: Does Zerodol SP cause drowsiness or make you feel sleepy?

A: Official documentation lists both dizziness and sleepiness (drowsiness) as possible side effects. Regulatory documents note that if these effects occur, caution is advised.

Q: Can Zerodol SP cause stomach upset or digestive issues?

A: Yes, common adverse events listed in official labeling are related to the digestive system. These include reports of dyspepsia (indigestion), abdominal pain, nausea, and diarrhea.

Q: Does Zerodol SP affect liver function?

A: Official documents note that the medicine may affect liver function. Increased liver enzymes (transaminases) are listed as a common side effect, and there is a documented risk of severe liver toxicity (hepatotoxicity) linked to the Paracetamol component, particularly with misuse.

Q: Is it okay to take Zerodol SP with antibiotics?

A: Official interaction guidance notes that the NSAID component, Aceclofenac, may have a documented interaction with certain types of antibiotics. Specifically, co-administration with quinolone antibiotics has been mentioned as potentially leading to convulsions.

Q: What should I do if I forget to take my scheduled dose of Zerodol SP?

A: Official dosage instructions describe that if a dose is missed, regulatory information generally states that the patient should take it as soon as it is remembered. However, if the next dose is almost due, it is generally advised that the missed dose be skipped rather than taking two doses close together.

Q: How should Zerodol SP be stopped? Should it be tapered?

A: Official documentation notes that the medicine should not be discontinued without consulting a healthcare professional. Treatment is also advised to be withdrawn if serious adverse reactions, such as gastrointestinal bleeding, occur.

Q: What is the official recommended duration of use for Zerodol SP?

A: Regulatory guidance emphasizes that the medication is intended for short-term use only. Official warnings note that administration for durations longer than four weeks is generally not recommended, based on a lack of sufficient safety and efficacy data for chronic use.

Q: Do studies support the combination of ingredients in Zerodol SP?

A: Clinical evidence has been gathered to investigate the combination’s role in managing pain and inflammation. Some studies have reported findings that the combination may show a quicker onset of pain relief compared to Aceclofenac used alone.

Q: Has Zerodol SP been researched for chronic pain conditions?

A: Official clinical evidence primarily focuses on the short-term management of acute conditions, such as post-operative pain and acute flare-ups of osteoarthritis. Regulatory warnings align with this, stating the drug is intended only for short-term use.

Q: What is the appropriate use for Zerodol SP according to regulatory bodies?

A: The appropriate use is officially described as the multimodal relief of symptoms where pain, inflammation, and associated swelling coexist. This is typically applied to musculoskeletal and postoperative conditions.

Q: Do official documents mention anything about Zerodol SP and alcohol consumption?

A: Yes. Official labeling contains a formal warning regarding alcohol use. It states that combining the Paracetamol component with alcohol consumption is linked to an enhanced risk of severe liver damage (hepatotoxicity) and may increase drowsiness.

Q: What is the purpose of Paracetamol in the Zerodol SP combination?

A: The Paracetamol component is included to provide analgesic (pain-relieving) and antipyretic (fever-reducing) effects. Its mechanism of action is primarily achieved by acting centrally within the nervous system.

Q: Are there any dietary restrictions mentioned in the official materials for Zerodol SP?

A: Official instructions mandate that the tablet should be taken with or immediately after food or milk. This procedure is intended to help minimize the risk of gastrointestinal irritation linked to the NSAID component. No specific dietary restrictions beyond this are noted.

Q: Can Zerodol SP affect the results of certain medical tests?

A: Official warnings note that the NSAID component, Aceclofenac, may interfere with blood clotting. Regulatory guidance advises that patients receiving long-term treatment require regular monitoring of blood counts and tests for renal and hepatic function.

Q: What does the patient information leaflet say about stopping Zerodol SP?

A: Official documentation notes that the medicine should not be discontinued without consulting a healthcare professional. Furthermore, it states that treatment must be withdrawn if serious adverse events (such as gastrointestinal bleeding) occur.

Q: Is Zerodol SP associated with any mental health or mood-related side effects?

A: Official documentation does not specifically list mental health or mood disorders as adverse events. However, it does list nervous system side effects such as dizziness, disorientation, and headache.

Q: Is it normal to feel a change in appetite while taking Zerodol SP?

A: Official documentation lists a change in appetite, specifically loss of appetite, as a Common side effect associated with the use of the medicine.

Q: Can Zerodol SP interact with any over-the-counter pain relievers?

A: Official labeling mandates formal restrictions on co-administration due to the risk of cumulative toxicity. This includes restrictions on taking it with other Non-steroidal Anti-inflammatory Drugs (NSAIDs) and any other products that contain Paracetamol.

Q: Is there a maximum number of days Zerodol SP is officially recommended for use?

A: Official documentation emphasizes that the drug is for short-term use and that administration beyond approximately four weeks is generally not recommended, based on a lack of sufficient safety and efficacy data for extended periods of use.

How should Zerodol SP be stored and disposed of?

The official labeling requires Zerodol SP tablets to be stored in a cool and dry environment, with the specific temperature constraint of storing below 30 C or 25 C.

Storage Conditions

Requirement	Official Labeled Condition
Temperature	Store below 30 C / controlled room temperature
Protection	Protect from light and moisture
Packaging	Store in the original container and keep it tightly closed

This medicine must be kept out of the sight and reach of children and pets at all times. The product is not recommended for use past the expiry date printed on the packaging, as proper storage is necessary to ensure stability throughout its shelf-life.

Disposal Instructions

To dispose of unused or expired Zerodol SP, the regulatory instruction is to consult a pharmacist or local waste disposal company. The final disposal procedure should be chosen to prevent consumption by children or pets and, where documented, to avoid disposal via the wastewater system.

Zerodol SP